The recommended dose of Disitamab Vedotin is generally 2.5 mg/kg every 2 weeks, administered via intravenous infusion. The specific dosage should be adjusted according to the patient’s body weight, disease condition and tolerability, and must be used strictly under medical supervision.
I. Standard Dosage and Administration
Routine dosage
For adults with body weight ≥40 kg, the single dose is 2.5 mg/kg, with a 2‑week treatment cycle. The recommended infusion duration is 30–90 minutes.
Dosage calculation
Dosage is calculated based on actual body weight. For example, a patient weighing 60 kg will receive a single dose of 150 mg (60 kg × 2.5 mg/kg).
Treatment duration
Treatment is continued until disease progression or unacceptable toxicities occur. Efficacy and safety should be evaluated regularly.
II. Dosage Adjustment Principles
Adjustment for adverse reactions
If ≥ Grade 3 neutropenia, peripheral neuropathy or other severe adverse reactions develop, dosing should be interrupted. Upon recovery, the dose should be reduced to 2.0 mg/kg.
If severe toxicity recurs, further dose reduction to 1.5 mg/kg or permanent discontinuation may be required.
Hepatic impairment
No dose adjustment is needed in patients with mild to moderate hepatic impairment. Caution and close monitoring are recommended in patients with severe hepatic impairment.
III. Precautions and Contraindications
Contraindicated populations
Contraindicated in patients with hypersensitivity to the drug components, and in pregnant or lactating women.
Infusion‑related reactions
Some patients may experience reactions such as fever and chills; preventive or symptomatic management is required.
Laboratory monitoring
During treatment, periodic monitoring of blood routine, hepatic and renal function, and neurological function is necessary.
IV. Storage and Preparation
Storage conditions
Unopened vials should be stored refrigerated at 2–8°C, protected from light, and must not be frozen.
Preparation method
Dilute with 0.9% Sodium Chloride Injection before use. Prepare immediately before administration; do not mix or infuse with other medicinal products.
Important note: Disitamab Vedotin is a prescription drug. The specific treatment regimen must be formulated by a physician based on the individual patient’s condition. Do not adjust the dosage or discontinue treatment without medical advice. Seek immediate medical attention if any abnormal symptoms occur during treatment.
